Juan Manuel Martinez-Alejo

Juan Manuel Martinez-Alejo

Auto-generated profile, based on publicly available information

Juan Manuel Martinez-Alejo

Centro de Investigación Sophia, Laboratorios Sophia SA de CV, Zapopan, Mexico

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2014 in Crystal Growth & Design
Verified
Journal Article
Closed access
JMJuan M. Martínez-Alejo
Juan M. Martínez-Alejo
JDJorge G. Domínguez-Chávez
Jorge G. Domínguez-Chávez
JRJESUS RIVERA
JESUS RIVERA
DHDea Herrera-Ruiz
Dea Herrera-Ruiz
HHHerbert Höpfl
Herbert Höpfl
JSJP Senosiain
JP Senosiain

1 November 2018 in Carbohydrate Polymers
Verified
Journal Article
Closed access
JMJuan Manuel Martinez-Alejo
Juan Manuel Martinez-Alejo
YBYaiza Benavent-Gil
Yaiza Benavent-Gil
CRCristina M Rosell
Cristina M Rosell
Teresa CarvajalTeresa Carvajal
Teresa Carvajal
MMMario M. Martinez
Mario M. Martinez

1 April 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
CMCarolina P. Mora
Carolina P. Mora
JMJuan Manuel Martinez-Alejo
Juan Manuel Martinez-Alejo
LRLaura Roman
Laura Roman
MMMario M. Martinez
Mario M. Martinez
TCTeresa Carvajal
Teresa Carvajal
CMClaudia E. Mora-Huertas
Claudia E. Mora-Huertas

2 December 2022 in Therapeutic Advances in Chronic Disease
Verified
Journal Article
Open access
JMJuan Manuel Martinez-Alejo
Juan Manuel Martinez-Alejo
LBLeopoldo Martin Baiza-Duran
Leopoldo Martin Baiza-Duran
JQJuan de Dios Quintana-Hau
Juan de Dios Quintana-Hau
Proliferative retinopathies, such as neovascular age–related macular degeneration and proliferative diabetic retinopathy, are a special health issue due to their contribution to irreversible blindness. Although the promoting conditions and physiopathology of proliferative retinopathies are different, these feature a highly detrimental angiogenesis driven by the overproduction of vascular endothelial growth factor (VEGF). This article describes the mechanism of action of ocular antiangiogenic therapies currently found in clinical development. Systems classify accordingly as (a) novel anti-VEGF systems, (b) molecules targeting non-VEGF pathways, and (c) gene therapies. Whereas most therapies are designed to neutralize VEGF, there is a significant set of products with diverse complexity and mechanism of action. Anti-VEGF therapies are still the most studied approach to tackle angiogenesis. Therapies targeting non-VEGF pathways, however, are highlighted because they could be an option for patients nonresponsive to anti-VEGF therapies. Finally, gene therapy is a promissory technology platform but still is subject to demonstrate safety and efficacy.